Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Opdivo 40 mg/4 mL injection for intravenous use Images

Generic Name: nivolumab

This medication has been identified as Opdivo 40 mg/4 mL injection for intravenous use. It is supplied by Bristol-Myers Squibb Company.

Opdivo is used in the treatment of Esophageal Carcinoma; Head and Neck Cancer; Colorectal Cancer; Hepatocellular Carcinoma; Hodgkin's Lymphoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Opdivo 40 mg/4 mL injection for intravenous use is not a controlled substance under the Controlled Substances Act (CSA).

Images

Opdivo (Nivolumab [ nye-vol-ue-mab ])-medicine-40 mg/4 mL injection for intravenous use

Opdivo
Generic Name: nivolumab [ nye-vol-ue-mab ]
Imprint: medicine
Strength: 40 mg/4 mL injection for intravenous use
Color: N/A
Size: N/A
Shape: N/A
Availability: Prescription only
Drug Class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Pregnancy Category: N/A
CSA Schedule: Not a controlled drug
Labeler / Supplier: N/A
National Drug Code (NDC): 00003-3772
Inactive Ingredients:
Latest News
Related Drugs